Health
Researchers develop ultrapotent miniproteins that target SARS-CoV-2 receptor-binding domain – News-Medical.Net
Researchers have investigated the effectiveness of a bioengineered miniprotein in protecting against SARS-CoV-2 infection in vivo. The researchers evaluated the…
Last September, researchers at the University of Washington, USA, reported the development of computer-designed small proteins – ‘miniproteins’ – that can target the receptor-binding domain (RBD) on the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic.
This work was published in the journal Science, claiming the lead antiviral miniprotein candidate, named LCB1, which exhibited better protective…
-
Noosa News19 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General19 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
General21 hours agoPerth man charged after investigation into organised crime and tobacco store attacks
-
General10 hours agoSmall-town cleaner finds himself in legal battle with EnduroShield over product packaging